Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Prescribing Statins to Reduce Cardiovascular Disease: 10 Common Misconceptions.

Schade DS, Shey L, Eaton RP.

Am J Med. 2019 Aug;132(8):897-899. doi: 10.1016/j.amjmed.2019.01.042. Epub 2019 Mar 6. No abstract available.

PMID:
30851261
2.

Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis.

Keller H, Hirsch O, Kaufmann-Kolle P, Krones T, Becker A, Sönnichsen AC, Baum E, Donner-Banzhoff N.

BMC Public Health. 2013 Jul 2;13:623. doi: 10.1186/1471-2458-13-623.

3.

Statin prescribing among hypertensive patients in southwest Nigeria: findings and implications for the future.

Akunne OO, Godman B, Adedapo AD, Truter I, Fadare J.

J Comp Eff Res. 2016 May;5(3):281-8. doi: 10.2217/cer.15.65. Epub 2016 Apr 20.

4.
5.

Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis.

Fleetcroft R, Schofield P, Ashworth M.

BMC Health Serv Res. 2014 Sep 20;14:414. doi: 10.1186/1472-6963-14-414.

6.

Statin Therapy Prescribing for Patients with Type 2 Diabetes Mellitus: A Review of Current Evidence and Challenges.

Elnaem MH, Mohamed MHN, Huri HZ, Azarisman SM, Elkalmi RM.

J Pharm Bioallied Sci. 2017 Apr-Jun;9(2):80-87. doi: 10.4103/jpbs.JPBS_30_17. Review.

7.

Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities.

Gnavi R, Migliardi A, Demaria M, Petrelli A, Caprioglio A, Costa G.

Eur J Public Health. 2007 Oct;17(5):492-6. Epub 2007 Feb 15.

PMID:
17303583
8.

Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.

Pichetti S, Sermet C, Godman B, Campbell SM, Gustafsson LL.

Appl Health Econ Health Policy. 2013 Jun;11(3):205-18. doi: 10.1007/s40258-013-0014-4.

PMID:
23609765
9.

Statin-prescribing trends for primary and secondary prevention of cardiovascular disease.

Brown F, Singer A, Katz A, Konrad G.

Can Fam Physician. 2017 Nov;63(11):e495-e503. Epub 2017 Nov 14.

10.

Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia.

Demoz GT, Wahdey S, Kasahun GG, Hagazy K, Kinfe DG, Tasew H, Bahrey D, Niriayo YL.

BMC Res Notes. 2019 Jul 9;12(1):386. doi: 10.1186/s13104-019-4423-9.

11.

Trends in prescribing rate of statins at discharge and modifiable factors in patients with atherosclerotic cardiovascular disease.

Huang BT, Peng Y, Huang FY, Xia TL, Gui YY, Liao YB, Pu XB, Chen SJ, Yang Y, Chen M.

Intern Emerg Med. 2017 Dec;12(8):1121-1129. doi: 10.1007/s11739-017-1694-9. Epub 2017 Jun 8.

PMID:
28597359
12.

Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study.

Wei L, MacDonald TM, Watson AD, Murphy MJ.

Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):385-92.

PMID:
16998946
13.

Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.

Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS.

JAMA Intern Med. 2016 Jun 1;176(6):763-8. doi: 10.1001/jamainternmed.2016.1709.

PMID:
27159336
14.
16.

Cardiovascular physiology misconceptions and the potential of cardiovascular physiology teaching to alleviate these.

Palizvan MR, Nejad MR, Jand A, Rafeie M.

Med Teach. 2013 Jun;35(6):454-8. doi: 10.3109/0142159X.2013.774331. Epub 2013 Mar 6.

PMID:
23464839
17.

Trends and variations in the prescribing of secondary preventative cardiovascular therapies for non-ST elevation myocardial infarction (NSTEMI) in Malaysia.

Venkatason P, Zaharan NL, Ismail MD, Wan Ahmad WA, Mahmood Zuhdi AS.

Eur J Clin Pharmacol. 2018 Jul;74(7):953-960. doi: 10.1007/s00228-018-2451-3. Epub 2018 Mar 26.

18.

Ongoing activities to optimize the quality and efficiency of lipid-lowering agents in the Scottish national health service: influence and implications.

Leporowski A, Godman B, Kurdi A, MacBride-Stewart S, Ryan M, Hurding S, Do Nascimento RC, Bennie M, Morton A.

Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):655-666. doi: 10.1080/14737167.2018.1501558. Epub 2018 Aug 3.

PMID:
30014725
19.

Patient and other factors influencing the prescribing of cardiovascular prevention therapy in the general practice setting with and without nurse assessment.

Mohammed MA, El Sayed C, Marshall T.

Med Decis Making. 2012 May-Jun;32(3):498-506. doi: 10.1177/0272989X12437246. Epub 2012 Feb 22.

PMID:
22357626
20.

The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002.

Teeling M, Bennett K, Feely J.

Br J Clin Pharmacol. 2005 Feb;59(2):227-32.

Supplemental Content

Support Center